No label defined (Q30296)

abstract

At the 2024 Conference on Retroviruses and Opportunistic Infections (CROI), investigators presented updates on the global HIV epidemic, focusing on ongoing disparities by race/ethnicity in the US, the ongoing concentration of new infections among men who have sex with men (MSM) and transgender women in the Americas, and a shift to a greater total number of infections now in low versus high [...] (English)

1

1 reference

HIV testing, the gateway to prevention and to treatment, has not fully rebounded from the substantial declines seen during the early COVID-19 pandemic in some settings, although innovative strategies including home testing and opt-out testing in clinical settings appear to be reaching populations in need of testing. (English)

2

1 reference

Several investigators reported on the efficacy and effectiveness of doxycycline used as postexposure prophylaxis (doxy-PEP) to prevent bacterial sexual transmitted infections in MSM and transgender women in clinical trials and clinic settings; citywide rates of chlamydia and syphilis have decreased in San Francisco after the rollout of the first doxy-PEP guidelines in the US. (English)

3

1 reference

Lack of doxy-PEP efficacy in cisgender women in Kenya appears due to low adherence in that trial. (English)

4

1 reference

Rollout and persistence on oral HIV preexposure prophylaxis (PrEP) are associated with reduced seroincidence on a population and individual level. (English)

5

1 reference

The rollout of long-acting injectable cabotegravir (CAB-LA) PrEP is proceeding slowly in the US. (English)

6

1 reference

New, longer-acting oral and injectable agents are in development, with preclinical and early clinical trial data presented at CROI. (English)

7

1 reference

Oral PrEP uptake among populations in sub-Saharan Africa remains low in most settings, suggesting the need for more options and more support; point-of-care tenofovir testing appear acceptable in various populations and may improve adherence and identify PrEP users needing more support. (English)

8

1 reference

Choice of PrEP or PEP including CAB-LA combined with clinical support substantially increased biomedical prevention coverage in East Africa. (English)

9

1 reference